galidesivir
Sponsors
BioCryst Pharmaceuticals
Conditions
COVID-19Marburg Virus DiseaseYellow Fever
Phase 1
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
CompletedNCT03800173
Start: 2018-12-10End: 2019-04-30Updated: 2021-07-23
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
TerminatedNCT03891420
Start: 2020-04-09End: 2021-04-30Updated: 2021-05-27